Clinical outcomes and predictive value of programmed cell death-ligand 1 expression in response to anti-programmed cell
- PDF / 1,441,986 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 40 Downloads / 246 Views
ORIGINAL ARTICLE
Clinical outcomes and predictive value of programmed cell death‑ligand 1 expression in response to anti‑programmed cell death 1/ligand 1 antibodies in non‑small cell lung cancer patients with performance status 2 or greater Takayuki Jodai1 · Koichi Saruwatari1 · Tokunori Ikeda2 · Eiji Moriyama3 · Kosuke Kashiwabara4 · Naoki Shingu5 · Kazuhiro Iyonaga6 · Megumi Inaba7 · Yusuke Ajishi8 · Chiharu Honda9 · Susumu Hirosako10 · Hirotaka Maruyama11 · Yosuke Kakiuchi12 · Hirofumi Eida13 · Yusuke Tomita1 · Sho Saeki1 · Hidenori Ichiyasu1 · Takuro Sakagami1 Received: 21 May 2020 / Accepted: 13 September 2020 © Japan Society of Clinical Oncology 2020
Abstract Background Anti-programmed cell death protein-1/ligand-1 (anti-PD-1/PD-L1) therapy is promising for patients with nonsmall-cell lung cancer (NSCLC); however, clinical trials have focused on patients with a performance status (PS) 0 or 1. This study aimed to evaluate the clinical outcomes and correlation between PD-L1 expression status and tumor response to anti-PD-1/PD-L1 therapy among NSCLC patients with poor PS (i.e., PS ≥ 2). Methods In total, 130 patients with NSCLC and PS ≥ 2 treated with anti-PD-1/PD-L1 monotherapy at 12 institutions between January 2016 and August 2019 were retrospectively reviewed. PD-L1 expression status was divided into four groups:
Data Loading...
